Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Joe Biden has proposed expanding the Inflation Reduction Act to include an increase in the number of prescription drugs subject to price negotiations from 20 to 50 annually. This proposal comes ahead of his State of the Union address. Novo Nordisk has reported positive Phase I data for their next-generation obesity candidate, showing a 13.1% reduction in body weight with a favorable safety profile. GSK has also advanced Blenrep's potential comeback with a second Phase III win in second-line multiple myeloma. Additionally, cancer-focused Boundless Bio has filed for an IPO to fund the development of novel cancer therapies targeting extrachromosomal DNA. ITF is preparing for an FDA decision on expanding the DMD market, AstraZeneca is investing in the UK for vaccine manufacturing and R&D, and Gilead and Merus have signed a potential $1.5 billion deal for T-cell engagers. This update also includes job listings in the biopharma industry.